Thalys(SH:603716)2023-04-26 16:00Financial Performance - In Q1 2023, the company reported revenue of CNY 444.07 million, a decrease of 23.29% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 14.91 million, representing a decline of 170% year-on-year[5]. - The basic earnings per share were CNY -0.07, a decrease of 173.25% compared to the same period last year[5]. - In Q1 2023, the company reported a net loss of CNY 6,651,427.65, compared to a net profit of CNY 25,738,000.43 in Q1 2022, indicating a significant decline in profitability[28]. - The company’s total comprehensive loss for the period was CNY 7,511,690.31, compared to a comprehensive income of CNY 21,546,216.99 in the same quarter last year[28]. Revenue Breakdown - The IVD business revenue was CNY 296.80 million, accounting for 66.79% of total revenue, down 5.91 percentage points from the previous year[7]. - Total operating revenue for Q1 2023 was ¥444,069,353.53, a decrease of 23.3% compared to ¥578,884,225.92 in Q1 2022[26]. - The total revenue from operating activities was CNY 587,950,514.74, an increase from CNY 459,800,471.28 in the same period last year, reflecting a growth of approximately 27.8%[29]. Expenses and Costs - Total expenses increased by 3.81% year-on-year to CNY 108 million, primarily due to increased sales and management expenses[10]. - Total operating costs for Q1 2023 were ¥455,311,016.55, down 15.7% from ¥540,110,563.59 in Q1 2022[26]. - Research and development expenses for Q1 2023 amounted to ¥7,450,644.90, a decrease of 13.6% from ¥8,630,117.36 in Q1 2022[26]. Cash Flow and Liquidity - The company’s cash flow from operating activities was CNY 38.64 million, which is not comparable to the previous period[5]. - The company reported a net cash flow from operating activities increase due to higher sales receipts[19]. - The company experienced a net cash flow from operating activities of CNY 38,642,551.81, a recovery from a negative cash flow of CNY 117,248,727.93 in Q1 2022[30]. - The company’s cash and cash equivalents decreased to 270.29 million from 394.54 million year-over-year[22]. - The company’s cash and cash equivalents at the end of Q1 2023 were CNY 261,908,897.81, down from CNY 406,322,679.30 at the end of Q1 2022, representing a decrease of approximately 35.5%[30]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3.74 billion, down 5.30% from the end of the previous year[6]. - Total assets decreased to ¥3,738,068,484.78 in Q1 2023 from ¥3,947,450,797.29 in Q1 2022, reflecting a decline of 5.3%[25]. - Total liabilities decreased by 34.67 million due to repayment of long-term borrowings[19]. - Total liabilities decreased to ¥2,246,130,033.44 in Q1 2023 from ¥2,450,479,523.67 in Q1 2022, a reduction of 8.3%[24]. - Current assets totaled ¥2,755,718,512.10 in Q1 2023, down from ¥2,950,562,653.79 in Q1 2022, a decrease of 6.6%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,534[18]. - The largest shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 25,042,470 shares, representing 12.30% of total shares[19]. Strategic Initiatives - The company is undergoing a strategic transformation towards medical intelligence, which has impacted revenue from traditional IVD business[6]. - The company received government grants totaling 364.60 million, contributing positively to other income[19].